This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

PRIMA Study Shows Treatment With Privigen® Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Stocks in this article: CSL

ROTTERDAM, Netherlands, June 27, 2012 /PRNewswire/ -- Data presented today from the Privigen Impact on Mobility and Autonomy (PRIMA) trial at the Peripheral Nerve Society Inflammatory Neuropathy Consortium Meeting in Rotterdam, Netherlands, suggests that treatment with Privigen® [Immune Globulin Intravenous (Human), 10% Liquid], an intravenous immunoglobulin (IVIg), may lead to improvement in function in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

PRIMA, a prospective, multicenter, open-label, single-arm study investigating the efficacy and safety of Privigen in previously IVIG-treated and untreated patients with CIDP achieved its primary efficacy endpoint, which was the percentage of patients responding—as measured by the Inflammatory Neuropathy Cause and Treatment (INCAT) scale—at study completion compared to baseline. The overall response rate was 60.7 percent. The 25-week treatment period permitted the observation that a response to IVIG can occur late (i.e., after more than 6 weeks of therapy). This finding may encourage some treating physicians to continue IVIG therapy longer in their CIDP patients before assessing whether or not the therapy is working. 

"CIDP is a rare, progressive disease that may cause permanent nerve damage and studies show that current treatment options may not work for all patients," said Jean-Marc Leger, M.D., Hospital de la Salpetriere. "Finding new treatment options to slow the advancement of the disease is extremely important. The results from this study are promising as they suggest that Privigen may help decrease weakness and loss of motor function in people with CIDP."

Functional improvement was evaluated by the INCAT scale, which is used to measure a patients' ability to perform tasks (i.e., walking, motor hand tasks, etc.). On this scale, patient scores rise with increasing weakness and disability, whereas improvement in basic motor functions is indicated by a reduction in the score. Results presented today showed that mean overall INCAT score significantly improved from 3.7 at baseline to 2.3 at completion of treatment. Half of the responders achieved the clinically meaningful threshold by Week 4.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs